Sarepta Therapeutics (SRPT) Drops 2% on Below Average Volume, Shares Now Trading at $106.89

This afternoon we watched Sarepta Therapeutics rise 2.0% to a price of $106.89 per share. The mid-cap Pharmaceutical company is now trading -39.05% below its average target price of $175.37. Analysts have set target prices ranging from $139.0 to $221.0 per share for Sarepta Therapeutics, and have given the stock an average rating of buy.

The stock has an average amount of shares sold short at 5.6%, and a short ratio of 3.83. Since 4.25% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 85.4% of Sarepta Therapeutics's shares being owned by this investor type.

Institutions Invested in Sarepta Therapeutics

Date Reported Holder Percentage Shares Value
2023-03-31 Vanguard Group Inc 9% 8,112,964 $867,154,174
2023-03-31 Blackrock Inc. 6% 5,282,695 $564,640,866
2023-03-31 Janus Henderson Group PLC 5% 4,908,204 $524,613,395
2023-03-31 JP Morgan Chase & Company 4% 3,702,944 $395,789,177
2023-03-31 Avoro Capital Advisors LLC 4% 3,650,000 $390,130,257
2023-03-31 EcoR1 Capital, LLC 3% 2,999,453 $320,596,540
2023-03-31 Wellington Management Group, LLP 3% 2,933,612 $313,559,124
2023-03-31 FMR, LLC 3% 2,644,656 $282,674,062
2023-03-31 Bank Of New York Mellon Corporation 2% 1,914,718 $204,654,637
2023-03-31 State Street Corporation 2% 1,773,976 $189,611,428

Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Sarepta Therapeutics.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.